@graham74GC @unnmf @Dr_Daniel_Molin Sorry I didn’t understand that patient remains EBV+ on blood. In that case would consider salvage when fit and allo. We have had some luck with dara, although follow up 32 pt study was disappointing https://t.co/CtyKm
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. #lymphoma #lymsm https://t.co/Ov79Fnw68l
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. by Huang H, Zhu J, Yao M, Kim TM, Yoon DH, Cho SG, Eom HS, Lim ST, Yeh SP, Song Y, Kwong …